Locanex: Targeted Search Tool


Therapeutic Strategies for the Management of Hormone ...

The behavior of HR /HER2 BC frequently differs from that of HR−/HER2 BC, and the two subtypes are increasingly being recognized as requiring different therapeutic approaches. HR /HER2 BC is a distinct subtype that presents clinical challenges in view of treatment optimization [6,7,8,9,10,11].

Understanding an HR or HER2- Breast Cancer Diagnosis

Breast cancer comes in many forms, and genetic and lifestyle factors can play a role. Here's what you need to know about a diagnosis of HR or HER2- breast cancer.

Study Evaluating Efficacy & Safety of Afuresertib Plus ...

Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR /HER2- Breast Cancer. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.

The Current State of CDK 4/6 Inhibitors in HR /HER2 ...

Xu B, Zhang Q, Zhang P, et al. Dalpiciclib versus placebo plus fulvestrant in HR /HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study. J Clin Oncol. 2021;39(suppl): Abstract 1002.


Locanex: Targeted Search Tool

[novo] Diretório Classificado em Português

2010-2021 LOCANEX ♣

Sat, 16 Oct 2021 18:53:25 +0000